https://twitter.com/Alazyinvestor13/status/1677943616290062339?s=20
Polymedicure KTA:
-
20% topline growth in FY24 with 25%+ margins.
-
Domestic biz will grow by 20-22% in FY24. Similar growth for exports.
-
Will launch Dialysis make-in-India machine (50% domestic content). Currently running on trial. Will make 200 machines in FY24.
-
Critical care biz - launched last year, will see more margins here.
-
Opportunity of US market is 15-20 million dollar in next 3-4 years.
| Subscribe To Our Free Newsletter |
